Common patterns of genetic evolution in human solid tumors

Cytometry

Volumn 29, Issue 1, 1997, Pages 1-27

  Shackney, Stanley E ^a   Shankey, T Vincent ^b,c  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^c HINES VA HOSPITAL   (United States)

Author keywords

Genetic evolution; Image analysis; Multiparameter flow cytometry; Oncogenes; Prognostic factors; Solid tumors; Tumor suppressor genes

Indexed keywords

ADENOSQUAMOUS CARCINOMA; ANEUPLOIDY; BREAST CANCER; CANCER GENETICS; CARCINOGENESIS; GENE OVEREXPRESSION; GENE SEQUENCE; HUMAN; IMAGE ANALYSIS; LUNG NON SMALL CELL CANCER; ONCOGENE C MYC; ONCOGENE NEU; ONCOGENE RAS; PRIORITY JOURNAL; REVIEW; SOLID TUMOR;

ANEUPLOIDY; DNA, NEOPLASM; FLOW CYTOMETRY; GENES, ERBB-2; GENES, MYC; GENES, RAS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MODELS, GENETIC; NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030883915     PISSN: 01964763     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0320(19970901)29:1<1::AID-CYTO1>3.0.CO;2-J     Document Type: Review

References (325)

1. Aaltonen LA, Peltomaki P, Leach FS, Sistonen P, Pylkkanen L, Mecklin J-K, Jarvinen H, Powell SM, Jen J, Hamilton SR, Petersen GM, Kinzler KW, Vogelstein B, de la Chapelle A: Clues to the pathogenesis of familial colorectal cancer. Science 260:812-816, 1993.
2. Aasmundstad TA, Hangen OA: DNA ploidy in intraductal breast carcinomas. Eur J Cancer 26:956-959, 1990.
3. Agarwal UL, Agarwal A, Taylor WR, Stark GR: p53 controls both the G2/M and G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc Soc Natl Acad Sci USA 92:8493-8497, 1995.
4. Alexander WS, Adams JM, Corny S: Oncogene cooperation in lymphocyte transformation. Malignant conversion of Eμ-myc transgeneic pre-B cells in vitro is enhanced by v-H-ras or v-raf but not v-abl. Mol Cell Biol 9:67-73, 1989.
5. Allred DC, Clark GM, Tandon AK, Molina R, Tormey DC, Osborne CK, Gilchrist KW, Mansour EG, Abeloff M, Eudey L, McGuire WL: Her-2/neu in node-negative breast cancer. Prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 10:599-605, 1992.
6. Antoniades K, Spector H: Correlation of estrogen receptor levels with histology and cytomorphology in human mammary cancer. Am J Clin Pathol 71:497-503, 1979.
7. Aprikian AG, Sarkis, AS, Fair WR, Zhang Z-F, Fuks Z, Cordon-Cardo C: Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma. J Urol 151:1276-1280, 1994.
8. Axelrod JH, Reich R, Miskin R: Expression of human recombinant plasminogen activators enhances invasion and experimental metastasis of H-ras transformed NIH 3T3 cells. Mol Cell Biol 9:2133-2141, 1989.
9. Bacus SS, Bacus JW, Slamon DJ, Press MF: Her-2/neu oncogene expession and DNA ploidy analysis in breast cancer. Arch Pathol Lab Med 114:164-169, 1990.
10. Bacus SS, Ruby SG, Weinberg DS, Chin D, Ortiz R, Bacus JW: Her-2/neu oncogene expression and proliferation in breast cancers. Am J Pathol 137:103-111, 1990.
11. Badalament RA, O'Toole RV, Young DC, Drago JR: DNA ploidy and prostate-specific antigen as prognostic factors in clinically resectable prostate cancer. Cancer 67:3014-3023, 1991.
12. Baker SJ, Fearon ER, Nigro JM, Hamilton SR, Preisinger AC, Jessup JM, vanTuinen P, Ledbetter DH, Barker DF, Nakamura Y, White R, Vogelstein B: Chromosome 17 deletions and p53 mutations in colorectal carcinomas. Science 244:217-221, 1989.
13. Baker SJ, Markowitz S, Fearon ER, Willson JKV, Vogelstein B: Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249:912-915, 1990.
14. Baker SJ, Preisinger AC, Jessup JM, Paraskeva C, Markowitz S, Willson JKV, Hamilton S, Vogelstein B: p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res 50:7717-7722, 1990.
15. Ballin M, Gomez DE, Sinha CC, Thorgeirsson UP: ras oncogene mediated induction of a 92kDa metalloproteinase: Strong correlation with the malignant phenotype. Biochem Biophys Res Commun 154:832-838, 1988.
16. Barbareschi M, Leonardi E, Mauri FA, Serio G, Palma PD: p53 and c-erbB-2 protein expression in breast carcinomas. Am J Clin Pathol 98:408-418, 1992.
17. Bartek J, Bartkova J, Vojtesek B, Staskova Z, Rejthar A, Kovarik J, Lane DP: Patterns of expression of the p53 tumour suppressor in human breast tissues and tumours in situ and in vitro. Int J Cancer 46:839-844, 1990.
18. Bennett WP, Colby TV, Travis WD, Borkowski A, Jones RT, Lane DP, Metcalf RA, Samet JM, Takeshima Y, Gu JR, Vahakangas KH, Soini Y, Paakko P, Welsh JA, Trump BF, Harris CC: p53 protein accumulates frequently in early bronchial neoplasia. Cancer Res 4817-4822, 1993.
19. Berger MS, Locher GW, Saurer S, Gullick WJ, Waterfield MD, Groner B, Hynes NE: Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res 1238-1243, 1988.
20. Berns EMJJ, Foekens JA, van Putten WLJ, van Staveren IL, Portengen H, de Koning WCH, Klun JGM: Prognostic factors in human primary breast cancer: Comparison of c-myc and Her-2/neu amplification. J Steroid Biochem Molec Biol 43:13-19, 1992.
21. Berns EMJJ, Klijn JGM, van Putten WLJ, van Staveren IL, Portengen H, Foekens JA: c-myc amplification is a better prognostic factor than Her-2/neu amplification in primary breast cancer. Cancer Res 52: 1107-1113, 1992.
22. Berns EMJJ, Klijn JGM, van Staveren IL, Portengen H, Noordegraaf E, Foekens JA: Prevalence of amplification of the oncogenes c-myc, Her2/neu, and int-2 in one thousand human breast tumors: Correlation with steroid receptors. Eur J Cancer 28:697-700, 1992.
23. Bichel P, Poulsen HS, Andersen J: Estrogen receptor content and ploidy of human mammary carcinoma. Cancer 50:1771-1774, 1982.
24. Bischoff FZ, Strong LC, Yim SO, Pratt DR, Siciliano MJ, Giovanella BC, Tainsky MA: Tumorigenic transformation of spontaneously immortalized fibroblasts from patients with a familial cancer syndrome. Oncogene 6:183-186, 1991.
25. Bischoff FZ, Yim SO, Pathak S, Grant G, Siciliano MJ, Giovanella BC, Strong LC, Tainsky MA: Spontaneous abnormalities in normal fibroblasts from patients with Li-Fraumeni Cancer syndrome: Aneuploidy and immortalization. Cancer Res 50:7979-7984, 1990.
26. Blount PL, Meltzer SJ, Yin J, Huang Y, Krasna MJ, Reid BJ: Clonal ordering of 17p and 5q allelic losses in Barrett's dysplasia and adenocarcinoma. Proc Natl Acad Sci USA 90:3221-3225, 1993.
27. Blount PL, Ramel S, Raskind WH, Haggitt RC, Sanchez CA, Dean PI, Rabinovitch PS, Reid BJ: 17p allelic deletions and p53 protein overexpression in Barrett's adenocarcinoma. Cancer Res 51:5482-5486, 1991.
28. Blount PL, Galipeau PC, Sanchez CA, Neshat K, Levine DS, Yin J, Suzuki H, Abraham JM, Meltzer SJ, Reid BJ: 17p allelic losses in diploid cells of patients with Barrett's esophagus who develop aneuploidy. Cancer Res 54:2292-2295, 1994.
29. Boland CR, Sato J, Appelman HD, Bresalier RS, Feinberg AP: Microallelotyping defines the sequence and tempo of allelic losses at tumor suppressor gene loci during colorectal cancer progression. Nature Med 1:902-909, 1995.
30. Bolufer P, Miralles F, Rodrigues A, Vasquez C, Lluch A, Garcia-Conde J, Olmos T: Epidermal growth factor receptor in human breast cancer: Correlation with cytosolic and nuclear ER receptors and with biological and histological tumor characterisitics. Eur J Cancer 26:283-290, 1990.
31. Bookstein R, MacGrogan D, Hilsenbeck SG, Sharkey F, Allred DC: p53 is mutated in a subset of advanced stage prostate cancers. Cancer Res 53:3369-3373, 1993.
32. Borg A, Baldetorp B, Ferno M, Killander D, Olsson H, Sigurdsson H: ERBB2 amplification in breast cancer with a high rate of proliferation. Oncogene 6:137-143, 1991.
33. Borg A, Baldetorp B, Ferno M, Olsson H, Sigurdsson H: c-myc amplification is an independent prognostic factor in postmenopausal breast cancer. Int J Cancer 51:687-691, 1992.
34. Borg A, Tandon AK, Sigurdsson H, Clark GM, Ferno M, Fuqua SAW, Killander D, McGuire WL: Her-2/neu amplification predicts poor survival in node positive breast cancer. Cancer Res 50:4332-4337, 1990.
35. Borg A, Zhang Q-X, Alm P, Olsson H, Sellberg G: The retinoblastoma gene in breast cancer: Allele loss is not correlated with loss of gene protein expression. Cancer Res 52:2991-2994, 1992.
36. Borresen A-L, Ottestad L, Gaustad A, Andersen TI, Heikkila R, Jahnsen T, Tveit KM, Nesland JM: Amplification and protein overexpression of the neu/Her2/c-erbB-2 protooncogene in human breast carcinomas: Relationship to loss of gene sequences on chromosome 17, family history and prognosis. Br J Cancer 62:585-590, 1990.
37. Bos JL, Fearon ER, Hamilton SR, Verlaan-de Vries M, van Boom JH, van der Eb AJ, Vogelstein B: Prevalence of ras gene mutations in human colorectal cancers. Nature 327:293-297, 1987.
38. Bose S, Lesser ML, Norton L, Rosen PP: Immunophenotype of intraductal carcinoma. Arch Path Lab Med 120:81-85, 1996.
39. Breivik J, Meling GI, Spurkland A, Rognum TO, Gaudernack G: K-ras mutation in colorectal cancer: Relations to patient age, sex, and tumour location. Br J Cancer 69:367-371, 1994.
40. Brentnall, TA, Crispin DA, Rabinovitch PS, Haggit RC, Rubin CE, Stevens AC, Burmer GC: Mutations in the p53 gene: An early marker of neoplastic progression in ulcerative colitis. Gastroenterology 107:369-378, 1994.
41. Brooks JD, Bova GS, Ewing CM, Piantadosi S, Carter BS, Robinson JC, Epstein JI, Isaacs WB: An uncertain role for p53 gene alterations in human prostate cancers. Cancer Res 56:3814-3822, 1996.
42. Bunn PA Jr, Carney DN, Gazdar AF, Whang-Peng J, Matthews MJ: Diagnostic and biological implications of flow cytometric DNA content analysis in lung cancer. Cancer Res 43:5026-5032, 1983.
43. Caleffi M, Teague MW, Jensen RA, Vnencak-Jones CL, Dupont WD, Parl FF: p53 gene mutations and steroid receptor status in breast cancer. Cancer 73:2147-2156, 1994.
44. Califano J, van der Riet P, Westra W, Nawroz H, Clayman G, Piantadosi S, Corio R, Lee D, Greenberg G, Koch W, Sidransky D: Genetic progression model for head and neck cancer: Implications for field cancerization. Cancer Res 56:2488-2492, 1996.
45. Campo E, de la Calle-Martin O, Miquel R, Palacin A, Romero M, Fabregat V, Vives J, Cardesa A, Yague J: Loss of heterozygosity of p53 gene and p53 protein expression in human colorectal carcinomas. Cancer Res 51:4436-4442, 1991.
46. Carder PJ, Cripps KJ, Morris R, Collins S, White S, Bird CC, Wyllie AH: Mutation of the p53 gene precedes aneuploid clonal divergence in colorectal carcinoma. Br J Cancer 71:215-218, 1995.
47. Casey G, Lo-Hsueh M, Lopez ME, Vogelstein B, Stanbridge EJ: Growth suppression of human breast cancer cells by the introducton of a wild-type p53 gene. Oncogene 6:1791-1797, 1991.
48. Cerny T, Barnes DM, Hasleton P, Barber PV, Healy K, Gullick W, Thatcher N: Expression of epidermal growth factor receptor (EGF-R) in human lung tumors. Br J Cancer 54:265-269, 1986.
49. Chambers AF, Denhardt GH, Wilson SM: ras-transformed NIH 3T3 cell lines, selected for metastatic ability in chick embryos, have increased proportions of p21-expressing cells and are metastatic in nude mice. Invasion Metastasis 10:225-240, 1990.
50. Cheickh MB, Rouanet P, Louason G, Jeanteur P, Theillet C: An attempt to define sets of cooperating genetic alterations in human breast cancer. Int J Cancer 51:542-547, 1992.
51. Chen L-C, Neubauer A, Kurisu W, Waldman FM, Ljung B-M, Goodson W III, Goldman ES, Moore Balazsom II, Liu E, Mayall BH, Smith HS: Loss of heterozygosity on the short arm of chromosome 17 is associated with high proliferative capacity and DNA aneuploidy in primary human breast cancer. Proc Natl Acad Sci USA 88:3847-3851, 1991.
52. Chen PL, Chen Y, Bookstein R, Lee WH: Genetic mechanisms for tumor suppression by the human p53 gene. Science 250:1576-1580, 1990.
53. Chiba I, Takahashi T, Nau MM, D'Amico D, Curiel DT, Mitsudomi T, Buchhagen DL, Carbone D, Piantadosi S, Koga H, Reissman PT, Slamon DJ, Holmes EC, Minna JD: Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Oncogene 5:1603-1610, 1990.
54. Chrysogelos SA, Yarden RI, Lauber AH, Murphy JA: Mechanisms of EGF receptor regulation in breast cancer cells. Breast Cancer Res Treat 31:227-236, 1994.
55. Cibas ES, Melamed MR, Zaman MB, Kimmel M: The effect of tumor size and tumor cell DNA content on the survival of patients with stage I adenocarcinoma of the lung. Cancer 63:1552-1556, 1989.
56. Ciocca DR, Fujimura FK, Tandon AK, Clark GM, Mark C, Lee-Chen G-J, Pounds GW, Vendely P, Owens MA, Pandian MR, McGuire WL: Correlation of Her-2/neu amplification with expression and with other prognostic factors in 1103 breast cancers. J Natl Cancer Inst 84:1279-1281, 1992.
57. Clair T, Miller WR, Cho-Chung YS: Prognostic significance of the expression of a ras protein with a molecular weight of 21,000 by human breast cancer. Cancer Res 47:5290-5293, 1987.
58. Clark GM, McGuire WL: Follow-up study of Her-2/neu amplification in primary breast cancer. Cancer Res 51:944-948, 1991.
59. Clark JS, George WD, Campbell AM: Dual colour flow cytometry of p53 and c-erbB-2 expression related to DNA aneuploidy in primary and metastatic breast cancer. Cancer Lett 66:193-200, 1992.
60. Cornelisse CJ, Kuipers-Dijkshoorn N, van Vliet M, Hermans J, Devilee P: Fractional allelic imbalance in human breast cancer increases with tetraploidization and chromosome loss. Int J Cancer 50:544-548, 1992.
61. Crissman JD, Visscher DW, Kubus J: Image cytophotometric DNA analysis of atypical hyperplasias and intraductal carcinomas of the breast. Arch Pathol Lab Med 114:1249-1253, 1990.
62. Cross SM, Sanchez CA, Morgan CA, Schimke MK, Ramel S, Idzerda RL, Raskind WH, Reid BJ: A p53-dependent mouse spindle checkpoint. Science 267:1353-1356, 1995.
63. Czerniak B, Chen R, Tuziak T, Markiewski M, Kram A, Gorczyca W, Deitch D, Herz F, Koss LG: Expression of ras oncogene p21 protein in relation to regional spread of human breast carcinomas. Cancer 63:2008-2013, 1989.
64. D'Amico D, Carbone D, Mitsudomi T, Nau M, Fedorko J, Russell E, Johnson B, Buchhagen D, Bodner S, Phelps R, Gazdar A, Minna JD: High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors. Oncogene 7:339-346, 1992.
65. Dati C, Antoniotti S, Taverna D, Perroteau I, De Bortoli M: Inhibition of c-erbB-2 oncogene expression by estrogens in human breast cancer cells. Oncogene 5:1001-1006, 1990.
66. Dati C, Muraca R, Tazartes O, Antoniotti S, Perroteau I, Giai M, Cortese P, Sismondi P, Saglio G, De Bortoli M: cErbB-2 and ras expression levels in breast cancer are correlated and show a co-operative association with unfavorable clinical outcome. Int J Cancer 47:833-838, 1991.
67. Davidoff AM, Kerns B-JM, Iglehart JD, Marks JR: Maintenance of p53 alterations throughout breast cancer progression. Cancer Research 51:2605-2610, 1991.
68. Davidson NE, Gelmann EP, Lippman ME, Dickson RB: Epidermal growth factor receptor gene expression in estrogen receptor-positive and negative human breast cancer cell lines. Molecular Endocrinol 1:216-223, 1987.
69. de Vries JE, Kornips FHAC, Marx P, Bosman FT, Geraedts JPM, ten Kate J: Transfected c-Ha-ras oncogene enhances karyotypic instability and integrates predominantly in aberrant chromosomes. Cancer Genet Cytogenet 65:35-43, 1993.
70. Dejter SW Jr, Cunningham RE, Noguchi PD, Jones RV, Moul JW, McCleod DG, Lynch JH: Prognostic significance of DNA ploidy in carcinoma of prostate. Urology 33:361-366, 1989.
71. Delarue JC, Friedman S, Mouriesse H, Levin F, Sancho-Garnier H, Contesso G: Epidermal growth factor receptor in human breast cancers: Correlation with estrogen and progesterone receptors. Breast Cancer Res Treat 11:173-178, 1988.
72. Delattre O, Law DJ, Remvikos Y, Sastre X, Feinberg AP, Olschwang S, Melot T, Salmon RJ, Validire P, Thomas G: Multiple genetic alterations in distal and proximal colorectal cancer. Lancet 2:353-356, 1989.
73. Denhardt DT, Greenberg AH, Egan SE, Hamilton RT, Wright JA: Cysteine proteinase cathepsin L expression correlates closely with the metastatic potential of H-ras-transformed murine fibroblasts. Oncogene 2:55-59, 1987.
74. Devilee P, van den Broek M, Kuipers-Dijkshoorn N, Kolluri R, Khan PM, Pearson PL, Cornelisse CJ: At least four different chromosomal regions are involved in loss of heterozygosity in human breast cancer. Genomics 5:554-560, 1989.
75. Domagala W, Markiewski M, Kubiak R, Bartkowiak J, Osborn M: Immunohistochemical profile of invasive lobular carcinoma of the breast: Predominantly vimentin and p53 protein negative, cathepsin D and oestrogen receptor positive. Virchows Arch A Pathol Anat 423:497-502, 1993.
76. Dougall WC, Qian X, Greene MI: Interaction of the neu/p185 and EGF receptor tyrosine kinases: Implications for cellular transformation and tumor therapy. J Cell Biochem 53:61-73, 1993.
77. Dressler LG, Seamer LC, Owens MA, Clark GM, McGuire WL: DNA flow cytometry and prognostic factors in 1331 frozen breast cancer specimens. Cancer 61:420-427, 1988.
78. Dutrillaux B, Gerbault-Seureau M, Remvikos Y, Zafrani B, Prieur M: Breast cancer genetic evolution. I. Data from cytogenetics and DNA content. Breast Cancer Res Treat 19:245-255, 1991.
79. Effert PJ, Neubauer A, Walther PJ, Liu ET: Alterations of the p53 gene are associated with the progression of a human prostate carcinoma. J Urol 147:789-793, 1992.
80. Egan SE, Broere JJ, Jarolim L, Wright JA, Greenberg AH: Co-regulation of metastatic and transforming activity of normal and mutant ras genes. Int J Cancer 43:443-448, 1989.
81. Egan SE, McClarty GA, Jarolim L, Wright JA, Spiro I, Hager G, Greenberg AH: Expression of H-ras correlates with metastatic potential: Evidence for direct regulation of the metastatic phenotype in 10T1/2 and NIH 3T3 cells. Mol Cell Biol 7:830-837, 1987.
82. Egan SE, Wright JA, Jarolim L, Yanagihara K, Bassin RH, Greenberg AH: Transformation by oncogenes encoding protein kinases induces the metastatic phenotype. Science 238:202-205, 1987.
83. Eliyahu D, Michalovitz D, Eliyahu S, Pibhasi-Kimhi O, Oren M: Wild-type p53 can inhibit oncogene-mediated focus formation. Proc Natl Acad Sci USA 86:8763-8767, 1989.
84. Eliyahu D, Raz A, Gruss P, Givol D, Oren M: Participation of p53 cellular tumour antigen in transformation of normal embryonic cells. Nature 312:646-649, 1984.
85. Elledge RM, Fuqua AW, Clark GM, Pujol P, Allred DC, McGuire WL: Prognostic significance of p53 gene alterations in node-negative breast cancer. Breast Cancer Res Treat 26:225-235, 1993.
86. Eriksson ET, Schimmelpenning H, Aspenblad U, Zetterberg A, Auer GU: Immunohistochemical expression of the mutant p53 protein and nuclear DNA content during the transition from benign to malignant breast disease. Hum Pathol 25:1228-1233, 1994.
87. Esrig D, Elmajian D, Groshen S, Freeman JA, Stein JP, Chen S-C, Nichols PW, Skinner DG, Jones PA, Cote RJ: Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 331:1259-1264, 1994.
88. Falco JP, Baylin SB, Lupu R, Borges M, Nelkin BD, Jasti RK, Davidson NE, Mabry M: v-rasH induces non-small cell phenotype, with associated growth factors and receptors, in a small cell lung cancer cell line. J Clin Invest 85:1740-1745, 1990.
89. Fallenius AC, Franzen SA, Auer GU: Predictive value of nuclear DNA content in breast cancer in relation to clinical and morphologic factors. Cancer 62:521-530, 1988.
90. Falor WH, Ward RM: Prognosis in early carcinoma of the bladder based on chromosomal analysis. J Urol 119:44-48, 1978.
91. Farsund T, Hoestmark JG, Laerum OD: Relation between flow cytometric DNA distribution and pathology in human bladder cancer. A report on 69 cases. Cancer 54:1771-1777, 1984.
92. Fearon ER Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 61:759-767, 1990.
93. Fidler IJ: Criticial factors in the biology of human cancer metastasis: Twenty-eighth G.H.A. Clowes Memorial Award Lecture. Cancer Res 50:6130-6138, 1990.
94. Finlay CA, Hinds PW, Levine AJ: The p53 proto-oncogene can act as a suppressor of transformation. Cell 57:1083-1093, 1989.
95. Finlay CA, Hinds PW, Tan T-H, Eliyahu D, Oren M, Levine AJ: Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 8:531-539, 1988.
96. Fitzpatrick SL, Brightwell J, Whitliff JL, Barrows GH, Schultz GS: Epidermal growth factor binding by breast tumor biopsies and relationship to estrogen and progestin receptor levels. Cancer Res 44:3448-3453, 1984.
97. Foekens JA, Portengen H, van Putten WLJ, Trapman AMAC, Reubi J-C, Alexieva-Figusch J, Klijn JGM: Prognostic value of receptors for insulin-like growth factor I, somatostatin, and epidermal growth factor in human breast cancer. Cancer Res 49:7002-7009, 1989.
98. Forrester K, Almoguera C, Han K, Grizzle WE, Perucho M: Detection of high incidence of K-ras oncogenes during colon tumorigenesis. Nature 327:298-303, 1987.
99. Frankel RH, Bayona W, Koslow M, Newcomb EW: p53 mutations in human malignant gliomas: Comparison of loss of heterozygosity with mutation frequency. Cancer Res 52:1427-1433, 1992.
100. Franza BR Jr, Maruyama K, Garrels JI, Ruley HE: In vitro establishment is not a sufficient prerequisite for transformation by activated ras oncogenes. Cell 44:409-418, 1986.
101. Frei JV: Hereditary nonpolyposis colorectal cancer (Lynch syndrome II), diploid malignancies with prolonged survival Cancer 69:1108-1111, 1992.
102. Fujii H, Marsh C, Cairns P, Sidransky D, Gabrielson E: Genetic divergence in the clonal evolution of breast cancer. Cancer Res 56:1493-1497, 1996.
103. Fukasawa K, Choi T, Kuriyama R, Rulong S, Vande Woude GF: Abnormal centrosome amplification in the absence of p53. Science 271:1744-1747, 1996.
104. Galipeau PC, Cowan DS, Sanchez CA, Barrett MT, Emond MJ, Levine DS, Rabinovitch PS, Reid BJ: 17P (p53) allelic losses, 4N (G2/ tetraploid) populations and progression to aneuploidy in Barrett's esophagus. Gastroenterology 110:A515, 1996 (abstract).
105. Gamou S, Hunts J, Harigai H, Hirohashi S, Shimosato Y, Pastan I, Shimizu N: Molecular evidence for the lack of epidermal growth factor receptor gene expression in small cell lung carcinoma cells. Cancer Res 47:2668-2673, 1987.
106. Garbisa S, Pozzatti R, Muschel RJ, Saffiotti U, Ballin M, Goldfarb RH, Khoury G, Liotta LA: Secretion of type IV collagenolytic protease and metastatic phenotype: Induction by transfection with c-Ha-ras but not c-Ha-ras plus Ad2-E1a. Cancer Res 47:1523-1528, 1987.
107. Garcia I, Dietrich P-Y, Aapro M, Vauthier G, Vadas L, Engel E: Genetic alterations of c-myc, c-erbB-2, and c-Ha-ras protooncogenes and clinical associations in human breast carcinoma. Cancer Res 49:6675-6679, 1989.
108. Gasparini G, Gullick WJ, Bevilaqua P, Sainsbury RC, Meli S, Boracchi P, Testolin A, La Malfa G, Pozza F: Human breast cancer: Prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features. J Clin Oncol 10:686-695, 1992.
109. Giaia M, Roagna R, Ponzone R, de Bortoli M, Dati C, Sismondi P: Prognostic and predictive relevance of c-erbB-2 and ras expression in node positive and negative breast cancer. Anticancer Res. 14:1441-1450, 1994.
110. Giaretti W, Monaco R, Pujic N, Rapallo A, Nigro S, Geido E: Intratumor heterogeneity of K-ras2 mutations in colorectal adenocarcinomas Association with degree of aneuploidy. Am J Pathol 149:237-245, 1996.
111. Gibas Z, Prout GR Jr, Connolly JG, Pontes JE, Sandberg AA: Nonrandom chromosomal changes in transitional cell carcinoma of the bladder. Cancer Res 44:1257-1264, 1984.
112. Gleason DF: Classification of prostatic carcinomas. Cancer Chemother Rep 50:125-128, 1966.
113. Graziano SL, Pfeifer AM, Testa JR, Mark GE, Johnson BE, Hallinan EJ, Pettengill OS, Sorenson GD, Tatum AH, Brauch H, Zbar B, Flejter WL, Ehrlich GD, Poiwsz BJ: Involvement of the RAF1 locus, at band 3p25, in the 3p deletion of small cell lung cancer. Genes Chromosomes Cancer 3:283-293, 1991.
114. Greene DR, Taylor SR, Wheeler TM, Scardino PT: DNA ploidy by image analysis of individual foci of prostate cancer: A preliminary report. Cancer Res 51:4084-4089, 1991.
115. Grimaux M, Romain S, Remvikos Y, Martin PM, Magdelenat H: Prognostic value of epidermal growth factor receptor in node-positive breast cancer. Breast Cancer Res Treat 14:77-90, 1989.
116. Guerin M, Barrois M, Terrier M-J, Spielmann M, Riou G: Overexpression of either c-myc or c-erbB-2/neu proto-oncogenes in human breast carcinomas: Correlation with poor prognosis. Oncogene Res 3:21-31, 1988.
117. Guerin M, Gabillot M, Mathieu M-C, Travagli J-P, Spielman M, Andrieu N, Riou G: Structure and expression of c-erbB-2 and EGF recptor genes in inflammatory and non-inflammatory breast cancer: Prognostic significance. Int J Cancer 43:201-208, 1989.
118. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Save-Soderborgh J, Anbazhagan R, Styles J, Rudenstam C-M, Gulough R, Reed R, Martinez-Tello F, Tiltman A, Torhorst J, Grigolato R, Bettelheim R, Neville AM, Burki K, Castiglione M, Collins J, Lindtner J, Senn H-J: Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 10:1049-1056, 1992.
119. Habuchi T, Ogawa O, Kakehi Y, Ogura K, Koshiba M, Sugiyama T, Yoshida O: Allelic loss of chromosome 17p in urothelial cancer: Strong association with invasive phenotype. J Urol 148:1595-1599, 1992.
120. Haeder M, Rotsch M, Bepler G, Hennig C, Havemann K, Heimann B, Moellins K: Epidermal growth factor receptor expression in human lung cancer cell lines. Cancer Res 48:1132-1136, 1988.
121. Hanna W, Kahn HJ, Andrulis I, Pawson T: Distribution and patterns of staining of neu oncogene product in benign and malignant breast diseases. Modern Pathol 3:455-461, 1990.
122. Harbour JW, Lai S-L, Whang-Peng J, Gazdar AF, Minna JD, Kaye FJ: Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science 241:353-357, 1988.
123. Harvey M, Sands AT, Weiss RS, Hegi ME, Wiseman RW, Pantazis P, Giovanella BC, Tainsky MA, Bradley A, Donehower LA: In vitro growth characterisitics of embryo fibroblasts isolated from p53 deficient mice. Oncogene 8:2457-2467, 1993.
124. Harvey M, Vogel H, Morris D, Bradley A, Bernstein A, Donehower LA: A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice. Nature Genet 9:305-311, 1995.
125. Hedley DW, Rugg CA, Gelber RD: Association of DNA index and S-phase fraction with prognosis of nodes positive early breast cancer. Cancer Res 47:4729-4735, 1987.
126. Heidenberg HB, Sesterhenn IA, Gaddipati JP, Weghorst CM, Buzard GS, Moul JW, Sarivastava S: Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer. J Urol 154:414-421, 1995.
127. Hensel CH, Hsieh CL, Gazdar AF, Johnson BE, Sokaguchi AY, Naylor SL, Lee H: Altered structure and expression of the human retinoblastoma susceptibility gene in small cell lung cancer. Cancer Res 50:3067-3072, 1990.
128. Hicks GG, Egan SE, Greenberg AH, Mowat M: Mutant p53 tumor suppressor alleles release ras-induced cell cycle growth arrest. Mol Cell Biol 11:1344-1352, 1991.
129. Hill SA, Wilson S, Chambers AF: Clonal heterogeneity, experimental metastatic ability, and p21 expression in H-ras-transformed NIH 3T3 cells. J Natl Cancer Inst 80:484-490, 1988.
130. Hinds P, Finlay C, Levine AJ: Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation. J Virol 63:739-746, 1989.
131. Hirakawa T, Ruley HE: Rescue of cells from ras oncogene-induced growth arrest by a second, complementing oncogene. Proc Natl Acad Sci USA 85:1519-1523, 1988.
132. Hopman AHN, Moesker O, Smeets AWGB, Ruud PE, Vooijs GP, Ramaekers FCS: Numerical chromosome 1, 7, 9, and 11 aberrations in bladder cancer detected by in situ hybridization. Cancer Res 51:644-651, 1991.
133. Horak E, Smith K, Bromley L, LeJeune S, Greenall M, Lane D, Harris AL: Mutant p53, EGF receptor and c-erbB-2 expression in human breast cancer. Oncogene 6:2277-2284, 1991.
134. Horowitz JM, Park S-H, Bogenmann E, Cheng J-C, Yandell DW, Kaye FJ, Minna JD, Dryja TP, Weinberg RA: Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. Proc Natl Acad Sci USA 87:2775-2779, 1990.
135. Horsfall DJ, Tilley WD, Orell SR, Marshall VR, Cant EL McK: Relationship between ploidy and steroid hormone receptors in primary invasive breast cancer. Br J Cancer 53:23-28, 1986.
136. Iggo R, Gatter K, Bartek J, Lane D, Harris AL: Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 335:675-679, 1990.
137. Iglehart JD, Kraus MH, Langton BC, Huper G, Kerns BJ, Marks JR: Increased erbB-2 gene copies and expression in multiple stages of breast cancer. Cancer Res 50:6701-6707, 1990.
138. Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M: Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 363:558-561, 1993.
139. Isaacs, WB, Bova GS, Morton RA, Bussemakers MJ, Brooks JD, Ewing CM: Genetic alterations in prostate cancer. Cold Spring Harbor Symp Quant Biol 59 653-659, 1994.
140. Isola J, Visakorpi T, Holli K, Kallioniemi O-P: Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 84:1109-1114, 1992.
141. Iwamoto KS, Mizuno T, Ito T, Tsuyama N, Kyoizumi S, Seyama T: Gain-of-function p53 mutations enhance alteration of the T-cell receptor following X-irradiation, independently of the cell cycle and cell survival. Cancer Res 56:3862-3865, 1996.
142. Janocko LE, Groft DW, Brown KA Smith CA, Pollice AA, Singh S, Lucke J, Yakulis R, Hartsock RJ, Shackney SE: Assessment of sequential oncogene amplification in human breast cancer. Cytometry 21:18-22, 1995.
143. Jen J, Powell SM, Papadopoulos N, Smith KJ, Hamilton SR, Vogelstein B, Kinzler KW: Molecular determinants of dysplasia in colorectal lesions. Cancer Res 54:5523-5526, 1994.
144. Jenkins JR, Rudge K, Currie GA: Cellular immortalization by a cDNA clone encoding the transformation-associated phosphoprotein p53. Nature 312:651-654, 1984.
145. Kallakuri BVS, Figge J, Ross JS, Fisher HAG, Figge HL, Jennings TA: Association of p53 immunoreactivity with high Gleason tumor grade in prostatic adenocarcinoma. Hum Pathol 25:92-97, 1994.
146. Kallionemi O-P, Kallionemi A, Kurisu W, Thor A, Chen L-C, Smith HS, Waldman FM, Pinkel D, Gray JW, ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc Natl Acad Sci USA 89:5321-5325, 1992.
147. Kallioniemi O-P, Blanco G, Alavaikko M, Hietanen T, Mattila J, Lauslahti K, Lehtinen M, Koivula T: Improving the prognostic value of DNA flow cytometry in breast cancer by combining DNA index and S-phases fraction. Cancer 62:2183-2190, 1988.
148. Kallioniemi O-P, Hietanen T, Mattila J, Lehtinen M, Lauslahti K, Koivula T: Aneuploid DNA content and high S-phase fraction of tumor cells are related to poor prognosis in patients with primary breast cancer. Eur J Cancer Clin Oncol 23:277-282, 1987.
149. Kaseda S, Ueda M, Ozawa S, Ishihara T, Abe O, Shimizu N: Expression of epidermal growth factor receptors in four histologic cell types of lung cancer. J Surg Oncol 42:16-20, 1989.
150. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW: Particpation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304-6311, 1991.
151. Her2 expression in human non-small cell lung cancer cell lines. Am J Respir Cell Mol Biol 6:359-363, 1992.
152. Kiefer PE, Bepler G, Kubasch M, Havemann K: Amplification and expression of protooncogenes in human small cell lung cancer cell lines. Cancer Res 47:6236-6242, 1987.
153. Kikuchi-Yanoshita R, Konishi M, Ito S, Seki M, Tanaka K, Maeda Y, Iino H, Fukayama M, Koike M, Mon T, Sakuraba H, Fukunari H, Iwama T, Miyaki M: Genetic changes of both p53 alleles associated with the conversion from colorectal adenoma to early carcinoma in familial adenomatous polyposis and non-familial adenomatous polyposis patients. Cancer Res 52:3965-3971, 1992.
154. Kim H, Jen J, Vogelstein B, Hamiltion SR: Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication Errors in microsatellite sequences. Am J Pathol 145:148-156, 1994.
155. King CR, Swain SM, Porter L, Steinberg SM, Lippman ME, Gelmann EP: Heterogeneous expression of erbB-2 messenger RNA in human breast cancer. Cancer Res 49:4185-4191, 1989.
156. Koenders PG, Beex LVAM, Geurts-Moespot A, Heuvel JJTM, Kienhuis CBM, Benraad TJ: Epidermal growth factor receptor-negative tumors are predominantly confined to the subgroup of estradiol receptor-positive human primary breast cancers. Cancer Res 51:4544-4548, 1991.
157. Konishi M, Kikuchi-Yanoshita R, Tanaka K, Muraoka M, Onda A, Okumura Y, Kishi N, Iwama T, Mori T, Koike M, Ushio K, Chiba M, Nomizu S, Konishi F, Utsunomiya J, Miyaki M: Molecular nature of colon tumors in hereditary nonpolyposis colon cancer, familial polyposis, and sporadic colon cancer. Gastroenterology 111:307-317, 1996.
158. Kouri M, Laasonen A, Mecklin J-P, Jarvinen H, Franssila K, Pyrhonen S: Diploid predominance in hereditary nonpolyposis colorectal carcinoma evaluated by flow cytometry. Cancer 65:1825-1829, 1990.
159. Kraus M, Popescu NC, Amsbaugh SC, King CR: Overexpression of the EGF receptor-related proto-oncogene erB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J 6:605-610, 1987.
160. Kreipe H, Feist H, Fischer I, Heidorn K, Meltler L, Parwaresch R: Amplification of c-myc but not of c-erbB-2 is associated with high proliferative capacity in breast cancer. Cancer Res 53:1956-1961, 1993.
161. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB: Wild-type 53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89:7491-7495, 1992.
162. Kyprianou N, Isaacs JT: Relationship between metastatic ability and H-ras oncogene expression in rat mammary cancer cells transfected with the v-H-ras oncogene. Cancer Res 50:1449-1454, 1990.
163. Land H, Parada LF, Weinberg RA: Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 304:596-602, 1983.
164. Land H, Parada LF, Weinberg RA: Cellular oncogenes and multistep carcinogenesis. Science 222:771-778, 1983.
165. Leal CB, Schmitt FC, Bento MJ, Maia NC, Lopes CS: Ductal carcinoma in situ of the breast:histologic categorization and its relationship to ploidy and immunohistochemical expression of hormone receptors, p53, and c-erbB-2 protein. Cancer 75:2123-2131, 1995.
166. Lee EY-HP, To H, Shew J-Y, Bookstein R, Scully P, Lee W-H: Inactivation of the retinoblastoma susceptibility gene in human breast cancers. Science 241:218-221, 1988.
167. Levine DS, Sanchez CA, Rabinovitch PS, Reid BJ: Formation of the tetraploid intermediate is associated with the development of cells with more than four centrioles in the elastase-simian virus 40 tumor antigen transgenic mouse model of pancreatic cancer. Proc Natl Acad Sci USA 88:6427-6431, 1991.
168. Lieber MM: Pathologic stage C (pT3) prostate cancer treated by radical prostatectomy: Clinical implications of DNA ploidy analysis. Seminars Urol 8:219-224, 1990.
169. Liu B, Nicolaides NC, Markowitz S, Willson JKV, Parsons RE, Jen J, Papadopolous N, Peltomaki P, de la Chapelle A, Hamilton SR, Kinzler KW, Vogelstein B: Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability. Nature Genet 9:48-55, 1995.
170. Liu E, Thor A, He M, Barcos M, Ljung B-M, Benz C: The Her2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast. Oncogene 7:1027-1032, 1992.
171. Livingstone LR, White A, Sprouse J, Livanos, Jacks T, Tlsty TD: Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70:923-935, 1992.
172. Lodato RF, Maguire HC Jr, Greene MI, Weiner DB, LiVolsi VA: Immunohistochemical evaluation of c-erbB-2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast. Modern Pathol 3:449-454, 1990.
173. Losi L, Fante R, di Gregorio C, Aisoni ML, Lanza G, Maestri I, Roncucci L, Pedroni M, Ponz de Leon M: Biologic characterization of hereditary nonpolyposis colorectal cancer. Am J Clin Pathol 103:265-270, 1995.
174. Lothe RA, Peltomaki P, Meling GI, Aaltonen LA, Nystrom-Lahti M, Pylkkanen L, Heimdal K, Andersen TI, Moller P, Rognum TO, Fossa SD, Haldorsen T, Langmark F, Brogger A, de la Chapelle A, Borresen A-L: Genomic instability in colorectal cancer: Relationship to clinicopathological variables and family history. Cancer Res 53:5849-5852, 1993.
175. Mabry M, Nakagawa T, Nelkin BD, McDowell E, Gesell M, Eggleston JC, Casero RA Jr, Baylin SB: v-Ha-ras oncogene insertion: A model for tumor progression of human small cell lung cancer. Proc Natl Acad Sci USA 85:6523-6527, 1988.
176. Magdelenat H, Gerbault-Seureau M, Laine-Bidron C, Prieur M, Dutrillaux B: Genetic evolution of breast cancer. II. Relationship with estrogen and progesterone expression. Breast Cancer Res Treat 22:119-127, 1992.
177. Marhin WW, Hei Y-J, Shaojun C, Jian Z, Gallie BC: Loss of Rb and myc activation co-operate to suppress cyclin D1 and contribute to transformation. Oncogene 12:43-52, 1996.
178. Martinez J, Georgoff I, Martinez J, Levine AJ: Cellular localization and cell cycle regulation by a temperature sensitive p53 protein. Genes Dev 5:151-159, 1991.
179. May E. Mouriesse H, May-Levin F, Qian JF, May P, Delarue J-C: Human breast cancer: Identification of populations with a high risk of early relapse in relation to both oestrogen receptor status and c-erbB-2 overexpression. Br J Cancer 62:430-435, 1990.
180. Mazars R, Spinardi L, BenCheikh M, Simony-Lafontaine J, Jeanteur P, Theillet C: p53 mutations occur in aggressive breast cancer. Cancer Res 52:3918-3923, 1992.
181. McCann AH, Dervan PA, O'Regan M, Codd MB, Gullick WJ, Tobin BMJ, Carney DN: Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer. Cancer Res 51:3296-3303, 1991.
182. McLaren R, Kuzu I, Dunnill M, Harris A, Lane D, Gatter KC: The relationship of p53 immunostaining to survival in carcinoma of the lung. Br J Cancer 66:735-738, 1992.
183. Meling GI, Lothe RA, Borresen A-L, Graue C, Hauge S, Clausen OPF, Rognum TO: The TP53 suppressor gene in colorectal carcinomas. II. relation to DNA ploidy pattern and clinicopathological variables. Br J Cancer 67:93-98, 1993.
184. Meltzer SJ, Yin J, Manin B, Rhyu M-G, Cottrell J, Hudson E, Redd JL, Krasna MJ, Abraham JM, Reid BJ: Microsatellite instability occurs frequently in both diploid and aneuploid cell populations of Barrett's-associated esophageal adenocarcinomas. Cancer Res 54:3379-3382, 1994.
185. Mercer WE, Amin M, Sauve GJ, Appella E, Ullrich SJ, Romano JW: Wild-type human p53 is antiproliferative in SV40-transformed hamster cells. Oncogene 5:973-980, 1990.
186. Mercer WE, Shields MT, Amin M, Sauve GJ, Appella E, Romano JW, Ullrich SJ: Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. Proc Natl Acad Sci USA 87:6166-6170, 1990.
187. Michalovitz D, Halevy O, Oren M: Conditional inhibition of transformation and of cell proliferation by a temperature sensitive mutant of p53. Cell 62:671-680, 1990.
188. Mikkelsen T, Cairncross JG, Cavanee WK: Genetics of the malignant progression of astrocytoma. J Cell Biochem 46:3-8, 1991.
189. Miller CW, Simon K, Aslo A, Kok K, Yokota J, Buys CHCM, Terada M, Koeffler HP: p53 mutations in human lung tumors. Cancer Res 52:1695-1698, 1992.
190. Miller G, Cygan JM: Diagnostic correlations with whole mounts of radical prostatectomy specimens. Monogr Pathol 34:183-197, 1992.
191. Minamato T, Yamashita N, Ochiai A, Mai M, Sugimura T, Ronai Z, Esumi H: Mutant K-ras in apparently normal mucosa of colorectal cancer patients. Cancer 75:1520-1526, 1994.
192. Mirchandani D, Zheng J, Miller GJ, Ghosh AK, Shibata DK, Cote RJ, Roy-Burman P: Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer. Am J Pathol 147:92-101, 1995.
193. Mitsudomi T, Viallet J, Mulshine R, Linnoila RI, Minna JD, Gazdar AF: Mutations of ras genes distinguish a subset of nonsmall-cell lung cancer cell lines from small-cell lung cancer cell lines. Oncogene 6:1353-1362, 1991.
194. Mizukami Y, Nonomura A, Noguchi M, Taniya T, Koyasaki N, Saito Y, Hashimoto T, Matsubara F, Yanaihara N: Immunohistochemical study of oncogene product ras p21, c-myc and growth factor EGF in breast carcinomas. Anticancer Res 11:1485-1494, 1991.
195. Moerkerk P, Arends JW, van Driel M, de Bruine A, de Goeij A, ten Kate J: Type and number of Ki-ras point mutations relate to stage of human colorectal cancer. Cancer Res 54:3376-3378, 1994.
196. Mohammed RH, Lakatua DJ, Haus E, Yasmineh WJ: Estrogen and progesterone receptors in human breast cancer. Correlation with histologic subtype and degree of differentiation. Cancer 58:1076-1081, 1986.
197. Montgomery BT, Nativ O, Blute ML, Farrow GM, Myers RP, Zincke H, Therneau TM, Lieber MM: Stage B prostate adenocarcinoma. Flow cytometric nuclear DNA ploidy analysis. Arch Surg 125:327-331, 1990.
198. Moody TW, Lee M, Kris RM, Bellot F, Bepler G, Oie H, Gazdar AF: Lung carcinoid cell lines have bombesin-like peptides and EGF receptors. J Cell Biochem 43:139-147, 1990.
199. Muleris M, Salmon R-J, Dutrillaux B: Cytogenetics of colorectal adenocarcinomas. Cancer Genet Cytogenet 46:143-156, 1990.
200. Navone NM, Troncoso P, Pisters LL, Goodrow TL, Palmer JL, Nichols WW, von Eschenbach AC, Conti CJ: p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 85:1657-1669, 1993.
201. Neshat K, Sanchez CA, Galipeau PC, Blount PL, Levine DS, Joslyn G, Reid BJ: p53 mutations in Barrett's adenocarcinoma and high grade dysplasia. Gastroenterology 106:1589-1595, 1994.
202. Nesland JM, Ottestad L, Heikilla R, Holm R, Tveit K, Borresen A-L: C-erbB-2 protein and neuroendocrine expression in breast carcinoma. Anticancer Res 11:161-168, 1991.
203. Nishio M, Koshikawa T, Kuroishi T, Suyama M, Uchida K, Takagi Y, Washimi O, Sugiuro T, Ariyoshi Y, Takahashi T, Ueda R, Takahashi T: Prognostic significance of abnormal p53 accumulation in primary, resected non-small-cell lung cancers. J Clin Oncol 14:497-502, 1996.
204. Norming U, Nyman CR, Tribukait B: Comparative flow cytometric deoxyribonucleic acid studies on exophytic tumor and random mucosal biopsies in untreated carcinoma of the bladder. J Urol 142:1442-1447, 1989.
205. Nowell PC: The clonal evolution of tumor cell populations. Science 194:23-28, 1976.
206. O'Malley FP, Vnencak-Jones CL, Dupont WD, Parl F, Manning S, Page DL: p53 mutations are confined to the comedo type ductal carcinoma in situ of the breast: Immunohistochemical and sequencing data. Lab Invest 71:67-72, 1994.
207. O'Reilly SM, Barnes DM, Camplejohn RS, Bartkova J, Gregory WM, Richards MA: The relationship between c-erbB2 expression, S-phase fractions and prognosis in breast cancer. Br J Cancer 63:444-446, 1991.
208. Offerhaus GJA, de Feyter EP, Cornelisse CJ, Tersmette WF, Floyd J, Kern SE, Vogelstein B, Hamilton SR: The relationship of DNA aneuploidy to molecular genetic alterations in colorectal carcinoma. Gastroenterology 102:1612-1619, 1992.
209. Ohuchi N, Thor A, Page DL, Horan Hand P, Halter SA, Schlom J: Expression of the 21,000 molecular weight ras protein in a spectrum of benign and malignant human mammary tissues. Cancer Res 46:2511-2519, 1986.
210. Olszewski W, Darzynkiewicz Z, Rosen PP, Schwartz MK, Melamed MR: Flow cytometry of breast carcinoma. I. Relation of DNA ploidy level to histology and estrogen receptor. Cancer 48:980-984, 1981.
211. Olumi AF, Tsai YC, Nichols PW, Skinner DG, Cain DR, Bender LI, Jones PA: Allelic loss of chromosome 17p distinguishes high grade from low grade transitional cell carcinoma of the bladder. Cancer Res 50:7081-7083, 1990.
212. Ornitz DM, Hammer RE, Messing A, Palmiter RD, Brinster RL: Pancreatic Neoplasia induced by SV40 T-antigen expression in acinar cells of transgenic mice. Science 238:188-193, 1987.
213. Otto E, McCord S, Tlsty TD: Increased incidence of CAD gene amplification in tumorigenic rat lines as an indicator of genomic instability of neoplastic cells. J Biol Chem 264:3390-3396, 1989.
214. Pandis N, Bardi G, Heim S: Interrelationship between methodological choices and conceptual models in solid tumor cytogenetics. Cancer Genet Cytogenet 76:77-84, 1994.
215. Pandis N, Jin Y, Limon J, Bardi G, Idvall I, Mandahl N, Mitelman F, Heim S: Interstitial deletion of the short arm of chromosome 3 as a primary chromosome abnormality in carcinomas of the breast. Genes Chromosomes Cancer 6:151-155, 1993.
216. Parada LF, Land H, Weinberg RA, Wolf D, Rotter V: Cooperation between genes encoding p53 tumor antigen and ras in cellular transformation. Nature 312:649-651, 1984.
217. Parkes HC, Lillycrop K, Howell A, Craig RK: C-erbB2 mRNA expression in human breast tumours: Comparison with c-erbB2 DNA amplification and correlation with prognosis. Br J Cancer 61:39-45, 1990.
218. Paulson TG, Wright FA, Parker BA, Russack V, Wahl GM: Microsatellite instability correlates with reduced survival and poor disease prognosis in breast cancer. Cancer Res 56:4021-4026, 1996.
219. Pekonen F, Partanen S, Makinen T, Rutanen E-M: Receptors for epidermal growth factor and insulin-like growth factor I and their relation steroid receptors in human breast cancer. Cancer Res 48:1343-1347, 1988.
220. Perucho M, Peinado MA, Ionov Y, Casanes S: Defects in replication fidelity of simple repeated sequences reveal a new mutator mechanism for oncogenesis. Cold Spring Harbor Symp Quant Biol 59:339-348, 1994.
221. Pfeifer AMA, Jones RT, Bowden PE, Mann D, Spillare E, Klein-Szanto AJP, Trump BR, Harris CC: Human bronchial epithelial cells transformed by the c-raf-1 and c-myc protooncogenes induce multidifferentiated carcinomas in nude mice: A model for lung carcinogenesis. Cancer Res 51:3793-3801, 1991.
222. Pfeifer AMA, Mark GE III, Malan-Shibley L, Graziano S, Amstad P: Cooperation of c-raf-1 and c-myc protooncogenes in the neoplastic transformation of simian virus 40 large tumor antigen-immortalized human bronchial epithelial cells. Proc Natl Acad Sci USA 86:10075-10079, 1989.
223. Battista P, Frati L, Bianco AR, Cama A, Costantini M: Microsatellite alterations and pathological aspects of breast cancer. Proc Am Assoc Cancer Res 37:546, 1996 (abst).
224. Poller DN, Roberts EC, Bell JA, Elston CW, Blamey RW, Ellis IO: p53 protein expression in mammary ductal carcinoma in situ: Relationship to immunohistochemical expression of estrogen receptor and c-erbB-2 protein. Hum Pathol 24:463-468, 1993.
225. Poller DN, Snead DRJ, Roberts EC, Galea M, Bell JA, Gilmour CW, Elston CW, Blamey RW, Ellis IO: Oestrogen receptor expression in ductal carcinoma in situ of the breast: Relationship to flow cytometric analysis of DNA and expression of the c-erbB-2 oncoprotein. Br J Cancer 68:156-161, 1993.
226. Porter PL, Garcia R, Moe R, Corwin DJ, Gown AM: C-erbB2 oncogene protein in in situ and invasive lobular breast neoplasia. Cancer 68:331-334, 1991.
227. Press MF, Pike MC, Chazin VR, Hung G, Udove JA, Markowitz M, Danyluk J, Godolphin W, Sliwkowski M, Akita R, Paterson MC, Slamon DJ: Her-2/neu expression in node-negative breast cancer: Direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 53:4960-4970, 1993.
228. Price JE, Bell C, Frost P: Use of a genotypic marker to demonstrate clonal dominance during the growth and metastasis of a human breast carcinoma in nude mice. Int J Cancer 45:968-971, 1990.
229. Rabinovitch PS, Reid BJ, Haggit RC, Norwood TH, Rubin CE: Progression to cancer in Barrett's esophagus is associated with genomic instability. Lab Invest 60:65-71, 1988.
230. Radford DM, Fair KL, Phillips NJ, Ritter JH, Steinbrueck T, Holt MS, Donis-Keller H: Allelotyping of ductal carcinoma in situ of the breast: Deletion of loci on 8p, 13q, 16q, 17p, and 17q. Cancer Res 55, 3399-3405, 1995.
231. +transformed 3T3 cells during tumor progression. Int J cancer 48:148-159, 1991.
232. Radinsky R, Kraemer PM, Proffitt MR, Culp LA: Clonal diversity of the Kirsten-ras oncogene during tumor progression in athymic nude mice:mechanisms of amplification and rearrangement. Cancer Res 48:4941-4953, 1988.
233. Radinsky R, Kraemer PM, Raines MA, Kung H-J, Culp LA: Amplification and rearrangement of the Kirsten ras oncogene in virus-transformed Balb/c 3T3 cells during malignant tumor progression. Proc Natl Acad Sci USA 84:5143-5147, 1987.
234. Ramachandra S, Machin L, Ashley S, Monaghan P, Gusterson BA: Immunohistochemical distribution of c-erbB-2 in in situ breast carcinoma-a detailed morphological analysis. J Pathol 161:7-14, 1990.
235. Ramel S, Reid BJ, Sanchez CA, Blount P, Levine DS, Neshat K, Haggit RC, Dean PJ, Thor K, Rabinovitch PS: Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry. Gastroenterology 102:1220-1228, 1992.
236. Ramel S, Sanchez CA, Schimke MK, Neshat K, Cross SM, Raskind WH, Reid BJ: Inactivation of p53 and the development of tetraploidy in the elastase-SV40 T antigen transgenic mouse pancreas. Pancreas 11:213-222, 1995.
237. Read LD, Keith D Jr, Slamon DJ, Katrzenellenbogen BS: Hormonal modulation of Her-2/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines. Cancer Res 50:3947-3951, 1990.
238. Reichmann A, Martin PM, Levin B: Chromosomal banding patterns in human large bowel cancer. Int J Cancer 28:431-440, 1981.
239. Reichmann A, Martin PM, Levin B: Marker chromosomes in direct preparations of human large bowel tumors. Cancer Genet Cytogenet 16:229-233, 1985.
240. Reid BJ, Blount PL, Rubin CE, Levine DS, Haggit RC, Rabinovitch PS: Flow cytometric and histological progression to malignancy in Barrett's esophagus: Prospective endoscopic surveillance of a cohort. Gastroenterology 102:1212-1219, 1992.
241. Remvikos Y, Laurent-Puig P, Salmon RJ, Frelat G, Dutrillaux B, Thomas G: Simultaneous monitoring of p53 protein and DNA content of colorectal adenocarcinomas by flow cytometry. Int J Cancer 45:450-456, 1990.
242. Remvikos Y, Vogt N, Muleris M, Salmon RJ, Malfoy B, Dutrillaux B: DNA-repeat instability is associated with colorectal cancers presenting minimal chromosome rearrangements. Genes Chromosom Cancer 12:272-276, 1995.
243. Ried T, Just KE, Holtgreve-Grez H, du Manoir S, Speicher MR, Schrock E, Latham C, Blegen A, Zetterberg A, Cremer T, Auer G: Comparative genomic hybridization of formalin-fixed, paraffin-embedded breast tumors reveals different patterns of chromosomal gains and losses in fibroadenomas and diploid and aneuploid carcinomas. Cancer Res 55:5415-5423, 1995.
244. Rio MC, Belloco JP, Gairard B, Rasmussen UB, Krust A, Koehl C, Calderoli H, Schiff V, Renaud R, Chambon P: Specific expression of the pS2 gene in subclasses of breast cancers in comparison with expression of the estrogen and progesterone receptors and the oncogene ERBB2. Proc Natl Acad Sci USA 84:9243-9247, 1987.
245. Risinger JL, Berchuck A, Kohler MF, Watson P, Lynch HT, Boyd J: Genetic instability of microsatellites in endometrial carcinoma. Cancer Res 53:5100-5103, 1993.
246. Robertson KW, Reeves JR, Smith G, Keith WN, Ozanne BW, Cooke TG, Stanton PD: Quantitative estimation of epidermal growth factor receptor and c-erbB-2 in human breast cancer. Cancer Res 56:3823-3830, 1996.
247. Rochlitz CF, Scott GK, Dodson JM, Liu E, Dollbaum C, Smith HS, Benz CC: Incidence of activating ras oncogene mutations associated with primary and metastatic human breast cancer. Cancer Res 49:357-360, 1989.
248. Rosen PP, Lesser ML, Arroyo CD, Cranor M, Borgen P, Norton L: p53 in node-negative breast carcinoma: An immunohistochemical study of epidemiological risk factors, histologic features, and prognosis. J Clin Oncol 13:821-830, 1995.
249. Roux-Dosseto M, Martin PM: A paradigm for oncogene complementation in human breast cancer. Res Virol 140:571-591, 1989.
250. Russell KS, Hung M-C: Transcriptional repression of the neu protooncogene by estrogen stimulated estrogen receptor. Cancer Res 52:6624-6629, 1992.
251. Ryan JJ, Danish R, Gottlieb CA, Clarke MF: Cell cycle analysis of p53-induced cell death in murine erythroleukemia cells. Mol Cell Biol 13:711-719, 1993.
252. Rygaard K, Vindelov LL, Spang-Thomsen M: Expression of myc family oncoproteins in small-cell lung-cancer cell lines and xenograpfts. Int J Cancer 54:144-152, 1993.
253. Sainsbury JRC, Farndon JR, Sherbet VJ, Harris AL: Epidermal-growth-factor receptors and estrogen receptors in human breast cancer. Lancet 1:364-366, 1985.
254. Sandberg AA: Chromosome markers and progression in bladder cancer. Cancer Res 37:2950-2956, 1977.
255. Sarkis AS, Dalbagni G, Cordon-Cardo C, Zhang Z-F, Sheinfeld J, Fair WR, Herr HW, Reuter VE: Nuclear overexpression of p53 protein in transitional cell bladder carcinoma. A marker for disease progression. J Natl Cancer Inst 85:53-59, 1993.
256. Sato T, Akiyama F, Sakamoto G, Kasumi F, Nakamura Y: Accumulation of genetic alteations and progression of primary breast cancer. Cancer Res 51:5794-5799, 1991.
257. Sauter G, Dang G, Moch H, Kerschmann R, Matsumura K, De Vries S, George T, Fuentes J, Carroll P, Mihatsch MJ, Waldman FM: Physical deletion of the p53 gene in bladder cancer. Detection by fluorescence in situ hybridization. Am J Pathol 144:756-766, 1994.
258. Schimmelpenning H, Eriksson ET, Pallis L, Skoog L, Cedermark B, Auer GU: Immunohistochemical c-erbB-2 proto-oncogene expression and nuclear DNA content in human mammary carcinoma in situ. Am J Clin Pathol 97:S548-S552, 1992.
259. Schneider PM, Hung M-C, Chiocca SM, Manning J, Zhao X, Fang K, Roth JA: Differential expression of the c-erbB-2 gene in human small cell and non-small cell lung cancer. Cancer Res 49:4968-4971, 1989.
260. Shackney S, Smith CA., Pollice, AA, Janocko LE, Singh SG, Groft DW, Brown KA, Hartsock RJ: Preferred genetic evolutionary sequences in human breast cancer: A case study. Cytometry 21:6-13, 1995.
261. Shackney SE, Berg G, Simon SR, Cohen J, Amina S, Pommersheim W, Yakulis R, Wang S, Uhl M, Smith CA, Pollice AA, Hartsock RJ: Origins and clinical implications of aneuploidy in early bladder cancer. Cytometry 22:307-316, 1995.
262. Shackney SE, Pollice AA, Smith CA, Alston L, Singh SG, Janocko LE, Brown KA, Petruolo S, Groft DW, Yakulis R, Hartsock RJ: The accumulation of multiple genetic abnormalities in individual tumor cells in human breast cancers: Clinical prognostic implications. Cancer J Sci Am 2:106-113, 1996.
263. Shackney SE, Singh S, Yakulis R, Smith CA, Pollice AA, Petruolo S, Waggoner A, Hartsock RJ: Aneuploidy in breast cancer. A fluorescence in situ hybridization study Cytometry 22:282-291, 1995.
264. Shackney SE, Smith CA, Miller BW, Burholt DR, Murtha KT, Giles HR, Ketterer DM, Pollice AA, Brown KA: Model for the genetic evolution of human solid tumors. Cancer Res 49:3344-3354, 1989.
265. Shi D, He G, Cao S, Pan W, Zhang HZ, Yu D, Hung MC: Overexpression of the c-erbB-2/neu-encoded p185 protein in primary lung cancer. Mol Carcinogenesis 5:213-218, 1992.
266. Shibata D, Navidi W, Salovaara R, Li Z-H, Aaltonen LA: Somatic microsatellite mutations as molecular tumor clocks. Nature Med 2:676-681, 1996.
267. Shibata D, Peinado MA, Ionov Y, Malkhosyian S, Perucho M: Genomic instability in repeated sequences is an early somatic event in colorectal tumorigenesis that persists after transformation. Nature Genet 6:273-281, 1994.
268. Shiraishi M, Noguchi M, Shimosato Y, Sekia T: Amplification of protooncogenes in surgical specimens of human lung carcinomas. Cancer Res 49:6474-6479, 1989.
269. Sidransky D, Frost P, Von Eschenbach A, Oyasu R, Preisinger AC, Vogelstein B: Clonal origin of bladder cancer. N Engl J Med 326:737-740, 1992.
270. Silvestrini R, Benini E, Daidone MG, Veneroni S, Boracchi P, Capelletti V, Di Fronzo G, Veronesi U: p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J Natl Cancer Inst 85:965-970, 1993.
271. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF: Studies of the Her-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989.
272. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: Correlation of relapse and survival with amplification of the Her-2/neu oncogene. Science 235:177-181, 1987.
273. Soderdahl G, Betsholtz C, Johansson A, Nilsson K, Bergh J: Differential expression of platelet-derived growth factor and transforming growth factor genes in small-and non-small-cell human lung carcinoma lines. Int J Cancer 41:636-641, 1988.
274. Sozzi G, Miozzo M, Donghi R, Pilotti S, Caraini CT, Pastorino U, Della Porta G, Pierotti MA: Deletions of 17p and p53 mutations in preneoplastic lesions of the lung. Cancer Res 52:6079-6082, 1992.
275. Spinucci C, Zucker S, Wieman JM, Lysik RM, Imhof B, Ramamurthy N, Liotta LA, Nagase H: Purification of a gelatin-degrading type IV collagenase secreted by ras oncogene-transformed fibroblasts. J Natl Cancer Inst 80:1416-1420, 1988.
276. Spruck CH III, Ohneseit PF, Gonzalez-Zulueta M, Esrig D, Miyao N, Tsai YC, Lerner SP, Schmutte C, Yang AS, Cote R, Dubeau L, Nichols PW, Hermann GG, Steven K, Horn T, Skinner DG, Jones PA: Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 54:784-788, 1994.
277. Stal O, Sullivan S, Sun X-F, Wingren S, Nordenskjold B: Simultaneous analysis of c-erbB-2 expression and DNA content in breast cancer using flow cytometry. Cytometry 16:160-168, 1994.
278. Stewart N, Hicks GG, Paraskevas F, Mowat M: Evidence for a second cell cycle block at G2/M by p53. Oncogene 10:109-115, 1995.
279. Sundaresan V, Ganly P, Hasleton P, Rudd R, Sinha G, Bleehen NM, Rabbitts P: p53 and chromosome 3 abnormalities, characteristic of malignant lung tumors, are detectable in preinvasive lesions of the bronchus. Oncogene 7:1989-1997, 1992.
280. Takahashi T, Carbone D, Takahashi T, Nau MM, Hida T, Linnoila I, Ueda R, Minna JD: Wild-type but not mutant p53 suppresses the growth of human lung cancer cells bearing multiple genetic lesions. Cancer Res 52:2340-2343, 1992.
281. Takahashi T, Obata Y, Sekido Y, Hida T, Ueda R, Watanabe H, Ariyoshi Y, Sugiura T, Takahashi T: Expression and amplification of myc gene family in small cell lung cancer and its relation to biological characterisitics. Cancer Res 49:2683-2688, 1989.
282. Tandon AK, Clark GM, Chamness GC, Ullrich A, McGuire WL: Her-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 7:1120-1128, 1989.
283. Tavassoli M, Quirke P, Farzaneh F, Lock NJ, Mayne LV, Kirkham N: C-erbB-2/c-erbA co-amplification indicative of lymph node metastasis, and c-myc amplification of high grade tumour, in human breast carcinoma. Br J Cancer 60:505-510, 1989.
284. Tetu B, Brisson J: Prognostic significance of Her-2/neu oncoprotein expression in node-positive breast cancer. Cancer 73:2359-2365, 1994.
285. Theillet C, Lidereau R, Escot C, Hutzell P, Brunet M, Gest J, Schlom J, Callahan R: Loss of a c-H-ras 1 allele and aggressive human primary breast carcinomas. Cancer Res 46:4776-4781, 1986.
286. Theodorescu D, Cornil I, Sheehan C, Man S, Kerbel RS: Dominance of metastatically competent cells in primary murine breast neoplasms is necessary for distant metastatic spread. Int J Cancer 47:118-123, 1991.
287. Thibodeau SN, Bren G, Schaid D: Microsatellite instability in cancer of the proximal colon. Science 260:816-819, 1993.
288. Thomas DJ, Robinson M, King P, Hasan T, Charleton R, Martin J, Carr TW, Neal DE: p53 Expression and clinical outcome in prostate cancer. Br J Urol 72:778-781, 1993.
289. Thor AD, Moore DH II, Edgerton SM, Kawasaki ES, Reihsaus E, Lynch HT, Marcus JN, Schwartz L, Chen L-C, Mayall BH, Smith HS: Accumulation of p53 tumor suppressor gene protein: An independent marker of prognosis in breast cancers. J Natl Cancer Inst 84:845-855, 1992.
290. Thor AD, Schwartz, LH, Koerner FC, Edgerton SM, Skates SJ, Yin S, McKenzie SJ, Panicali DL, Marks PJ, Fingert HJ, Wood WC: Analysis of c-erbB-2 expression in breast carcinomas with clinical followup. Cancer Res 49:7147-7152, 1989.
291. Tlsty TD: Normal diploid human and rodent cells lack a detectable frequency of gene amplification. Proc Natl Acad Sci USA 87:3132-3136, 1990.
292. Tlsty TD, Margolin BH, Lum K: Differences in the rates of gene amplification in non-tumorigenic and tumorigenic cell lines as measured by Luria-Delbruck fluctuation analysis. Proc Natl Acad Sci USA 86:9441-9445, 1989.
293. Toi M, Hamada Y, Nakamura T, Mukaida H, Suehiro S, Wada T, Toge T, Niimoto M, Hattori T: Immunocytochemical and biochemical analysis of epidermal growth factor receptor expression in human breast cancer tissues: Relationship to estrogen receptor and lymphatic invasion. Int J Cancer 43:220-225, 1989.
294. Trent J, Yang J-M, Emerson J, Dalton W, McGee D, Massey K, Thompson F, Villar H: Clonal chromosome abnormalities in human breast carcinomas. II. thirty four cases with metastatic disease. Genes Chromosom Cancer 7:194-203, 1993.
295. Tribukait B, Gustafson H, Esposti P-L: The significance of ploidy and proliferation in the clinical and biological evaluation of bladder tumours: A study of 100 untreated cases. Br J Urol 54:130-135, 1982.
296. Trudel M, Mulligan L, Cavanee W, Margolese R, Cote J, Gariepy G: Retinoblastoma and p53 gene product expression in breast carcinoma: Immunohistochemical analysis and clinicopathologic correlation. Hum Pathol 23:1388-1394, 1992.
297. Tsuda H, Fukutomi T, Hirohashi S: Pattern of gene alterations in intraductal breast neoplasms associated with histologic type and grade. Clin Cancer Res 1:261 -267, 1995.
298. Tsuda H, Hirohashi S, Shimosato Y, Hirota T, Tsugane S, Yamamato H, Miyajima N, Toyoshima K, Yamamato T, Yokota J, Yoshida T, Sakmoto H, Terada M, Sugimura T: Correlatation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units:hst-1/int-2 and c-erbB-2/ear-1. Cancer Res 49:3104-3108, 1989.
299. Tsuda H, Iwaya K, Fukutomi T, Hirohashi S: p53 mutations and c-erbB-2 amplification in intraductal and invasive breast carcinomas of high histologic grade. Jpn J Cancer Res 84:394-401, 1993.
300. Tuck AB, Wilson SM, Khokha R, Chambers AF: Different patterns of gene expression in ras-resistant and ras-sensitive cells. J Natl Cancer Inst 83:485-491, 1991.
301. Van de Vijver MJ, Peterse JL, Mooi WJ, Wisman P, Lomans J, Dalasio O, Nusse R: Neu-protein overexpression in breast cancer: Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 319:1239-1245, 1988.
302. van Agthoven T, Timmermans M, Foekens JA, Dorssers LCJ, Henzen-Logmans SC: Differential expression of estrogen, progesterone, and epidermal growth factor receptors in normal, benign, and malignant human breast tissues using dual staining immunohistochemistry. Am J Pathol 144:1238-1246, 1994.
303. Varley JM, Armour J, Swallow JE, Jeffreys AJ, Ponder BAJ, T'Ang A, Fung Y-KT, Brammar WJ, Walker RA: The retinoblastoma gene is frequently altered leading to loss of expression in primary breast tumors. Oncogene 4:725-729, 1989.
304. Vesalainen SLB, Lipponen PK, Talia MT, Alhava EM, Syrjanen KI: Proliferating cell nuclear antigen and p53 expression as prognostic factors in T1-2M0 prostatic adenocarcinoma. Int J Cancer 58:303-308, 1994.
305. Vindelov LL, Hansen HH, Christensen IJ, Spang-Thomsen M, Hirsch FR, Hansen M, Nissen NI: Clonal heterogeneity of small-cell anaplastic carcinoma of the lung demonstrated by flow-cytometric DNA analysis. Cancer Res 40:4295-4300, 1980.
306. Visakorpi T, Kallioniemi O-P, Heikkinen A, Koivula T, Isola J: Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst 84:883-887, 1992.
307. Visscher DW, Sarkar FH, Crissman JD: Correlations of DNA ploidy with c-erbB-2 expression in preinvasive and invasive breast tumors. Analyt Quant Cytol Histol 13:418-424, 1991.
308. Voeller HJ, Sugars LY, Pretlow T, Gelmann EP: p53 oncogene mutations in human prostate cancer specimens. J Urol 151:492-495, 1994.
309. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AMM, Bos JL: Genetic alterations during colorectal tumor development. N Engl J Med 319:525-532, 1988.
310. Wahl G, Yin Y, Tainsky MA, Bischoff FZ, McGill J, Forseth B, Von Hoff DD: Gene amplification in human cancer cells: Genes affecting its occurrence, and strategies for eliminating amplified genes. Proc Am Assoc Cancer Res 33:584-585, 1992.
311. Walker RA, Dearing SJ, Lane DP, Varley JM: Expression of p53 protein in infiltrating and in situ breast carcinomas. J Pathol 165:203-211, 1991.
312. Warri AM, Laine AM, Majasuo KE, Alitalo KK, Harkonen PL: Estrogen suppression of erbB2 expression is associated with increased growth rate of ZR-75-1 human breast cancer cells in vitro and nude mice. Int J Cancer 49:616-623, 1991.
313. Watson DMA, Elton RA, Jack WJL, Dixon JM, Chetty U, Miller WR: The H-ras oncogene product p21 and prognosis in human breast cancer. Breast Cancer Res Treat 17:161-169, 1990.
314. Whang-Peng J, Bunn PA, Kao-Shan CS, Lee EC, Carney DN, Gazdar A, Minna JD: A nonrandom chromosomal abnormality, del 3p(14-23) in human small-cell lung cancer (SCLC). Cancer Genet Cytogenet 6:119-134, 1982.
315. Whang-Peng J, Kao-Shan CS, Lee EC, Bunn PA, Carney DN, Gazdar AF, Minna JD: Specific chromosome defect associated with human small-cell lung cancer: Deletion 3p(14-23). Science 215:181-182, 1981.
316. Winkler HZ, Rainwater LM, Myers RP, Farrow GM, Therneau TM, Zincke H, Lieber MM: Stage D1 prostatic adenocarcinoma: Significance of nuclear DNA ploidy patterns studied by flow cytometry. Mayo Clin Proc 63:103-112, 1988.
317. Wright JA, Smith HS, Watt FM, Hancock MC, Hudson DL, Stark GR: DNA amplification is rare in normal human cells. Proc Natl Acad Sci USA 87:1791-1795, 1990.
318. Yamamoto T, Kamata N, Kawano H, Shimizu S, Kuroki T, Toyoshima K, Rikimaru K, Nomura N, Ishizaki R, Pastan I, Gamou S, Shimizu N: High incidence of amplification of the epidermal growth factor receptor gene in human squamous carcinoma cell lines. Cancer Res 46:414-416, 1986.
319. Yee CJ, Roodi N, Verrier CS, Parl FF: Microsatellite instability and loss of heterozygosity in breast cancer. Cancer Res 54:1641-1644, 1994.
320. Yin Y, Tainsky MA, Bischoff FZ, Strong LC, Wahl GM: Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant
321. Younes M, Lebovitz RM, Lechago LV, Lechago J: p53 protein accumulation in Barrett's metaplasia, dysplasia, and carcinoma: A followup study. Gastroenterology 105:1637-1642, 1993.
322. Zafrani B, Leroyer A, Fourquet A, Laurent M, Trophilme D, Validire P, Sastre-Garau X: Mammographically-detected ductal in situ carcinoma of the breast analyzed with a new classificiation. A study of 127 cases: Correlation with estrogen and progesterone receptors, p53 and c-erbB-2 proteins, and proliferative activity. Semin Diagn Pathol 11:208-214, 1994.
323. Zambetti GP, Levine AJ: A comparison of the biological activities of wild-type and mutant p53. FASEB J 7:855-865, 1993.
324. Zeillinger R, Kury F, Czerwenka K, Kubista E, Sliutz G, Knogler W, Huber J, Zielinski C, Reiner G, Jakesz R, Staffen A, Reiner A, Wrba F, Spona J: Her-2 amplification, steroid receptors and epidermal growth factor receptor in primary breast cancer. Oncogene 4:109-114, 1989.
325. Zoll B, Kynast B, Corell B, Marx D, Fischer G, Schauer A: Alterations of the c-erbB2 gene in human breast cancer. J Cancer Res Clin Oncol 118:468-473, 1992.